THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2016

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2016

MARKETPLACE

New pathology lab products and industry news

Home » MARKETPLACE, Marketplace Archives

Myriad launches EndoPredict, 7/17

 

July 2017—Myriad Genetics has launched the EndoPredict test in the U.S. for patients with ER+ HER2- early stage breast cancer. EndoPredict is a second-generation test for assessing the 10-year risk of disease recurrence following surgery and for determining which patients can safely forgo adjuvant chemotherapy.

EndoPredict is supported by multiple prospective clinical studies and data from more than 3,500 patients with ER+ HER2- node negative and node positive early stage breast cancer. The results of the clinical development program show that EndoPredict substantially outperforms the first-generation breast cancer recurrence tests. The test was trained and validated using 10-year outcomes data and includes proliferation-related genes as well as hormone receptor-related genes, providing accurate assessment of early and late risk for recurrence and definitively classifies patients as low or high risk.

Myriad Genetics, 801-584-3600

Tags:

X